166 related articles for article (PubMed ID: 24241205)
21. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Duebgen M; Martinez-Quintanilla J; Tamura K; Hingtgen S; Redjal N; Wakimoto H; Shah K
J Natl Cancer Inst; 2014 Jun; 106(6):dju090. PubMed ID: 24838834
[TBL] [Abstract][Full Text] [Related]
22. Response.
Martinez-Quintanilla J; Shah K
J Natl Cancer Inst; 2015 Jan; 107(1):370. PubMed ID: 25473105
[No Abstract] [Full Text] [Related]
23. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.
Sgubin D; Wakimoto H; Kanai R; Rabkin SD; Martuza RL
Stem Cells Transl Med; 2012 Apr; 1(4):322-32. PubMed ID: 23197811
[TBL] [Abstract][Full Text] [Related]
25. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
26. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
[TBL] [Abstract][Full Text] [Related]
27. Design and application of oncolytic HSV vectors for glioblastoma therapy.
Grandi P; Peruzzi P; Reinhart B; Cohen JB; Chiocca EA; Glorioso JC
Expert Rev Neurother; 2009 Apr; 9(4):505-17. PubMed ID: 19344302
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic viral therapy.
Inam Ur Rehma S; Haaris SM
J Pak Med Assoc; 2017 Apr; 67(4):658. PubMed ID: 28420939
[No Abstract] [Full Text] [Related]
29. Oncolytic HSV as a vector in cancer immunotherapy.
Li H; Zhang X
Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
[TBL] [Abstract][Full Text] [Related]
30. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
Alvarez-Breckenridge CA; Yu J; Price R; Wojton J; Pradarelli J; Mao H; Wei M; Wang Y; He S; Hardcastle J; Fernandez SA; Kaur B; Lawler SE; Vivier E; Mandelboim O; Moretta A; Caligiuri MA; Chiocca EA
Nat Med; 2012 Dec; 18(12):1827-34. PubMed ID: 23178246
[TBL] [Abstract][Full Text] [Related]
31. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.
Li QX; Liu G; Zhang X
Curr Pharm Biotechnol; 2012 Jul; 13(9):1773-85. PubMed ID: 21740353
[TBL] [Abstract][Full Text] [Related]
32. Virotherapy: The next addition to the standard of care for glioblastoma?
Broekman MLD; Nieland L; Hoeben RC
Cancer Cell; 2022 Oct; 40(10):1089-1091. PubMed ID: 36179688
[TBL] [Abstract][Full Text] [Related]
33. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
34. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
35. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
[TBL] [Abstract][Full Text] [Related]
36. EXPRESSION OF CONCERN: Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Int J Cancer; 2024 Sep; 155(5):E6. PubMed ID: 38773742
[TBL] [Abstract][Full Text] [Related]
37. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
[TBL] [Abstract][Full Text] [Related]
38. Turning killer into cure -- the story of oncolytic herpes simplex viruses.
Zhang SX
Discov Med; 2015 Nov; 20(111):303-9. PubMed ID: 26645902
[TBL] [Abstract][Full Text] [Related]
39. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM
Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554
[TBL] [Abstract][Full Text] [Related]
40. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
